Sharma, Manish R.

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

Luke, J. J., Lemons, J. M., Karrison, T. G., Pitroda, S. P., Melotek, J. M., Zha, Y., Al-Hallaq, H. A., Arina, A., Khodarev, N. N., Janisch, L., et al. (2018) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersAdvanced Radiotherapy Techniques

Cited by 588

Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

Pectasides, E., Stachler, M. D., Derks, S., Liu, Y., Maron, S., Islam, M., Alpert, L., Kwak, H., Kindler, H., Polite, B., et al. (2018) · Cancer Discovery

Cancer Genomics and DiagnosticsEsophageal Cancer Research and Treatment

Cited by 307

Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule

Berezhnoy, A., Sumrow, B. J., Stahl, K., Shah, K., Liu, D., Li, J., Hao, S.-S., De Costa, A., Kaul, S., Bendell, J., et al. (2020) · Cell Reports Medicine

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 56

Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium

Sharma, M. R., Wroblewski, K., Polite, B. N., Knost, J. A., Wallace, J. A., Modi, S., Sleckman, B. G., Taber, D., Vokes, E. E., Stadler, W. M., et al. (2012) · Investigational New Drugs

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 49

Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors.

Jang, S., Powderly, J. D., Spira, A. I., Bakkacha, O., Loo, D., Bohac, G. C., & Sharma, M. (2021) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 46

AVID200, first‐in‐class TGF‐beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose‐escalation study in patients with advanced solid tumors

Yap, T. A., Lakhani, N. J., Araujo, D. V., Rodon Ahnert, J., Chandana, S. R., Sharma, M., Denis, J.-F., Gruosso, T., Tremblay, G., O'Connor, M., et al. (2020) · Journal of Clinical Oncology

TGF-β signaling in diseasesCancer Immunotherapy and Biomarkers

Cited by 26

First-in-human phase 1/2 dose escalation and expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with solid tumors.

Meric-Bernstam, F., Sharma, M., Sommerhalder, D., Skeel, R. T., El-Khoueiry, A. B., Caswell-Jin, J. L., Patel, P. H., & Rosen, E. (2022) · Journal of Clinical Oncology

RNA and protein synthesis mechanismsPI3K/AKT/mTOR signaling in cancer

Cited by 17

COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies (NCT03667716).

Vaena, D. A., Fleming, G. F., Chmielowski, B., Sharma, M., Hamilton, E. P., Sullivan, R. J., Shepard, D. R., Papadopoulos, K. P., Patnaik, A., ElNaggar, A., et al. (2021) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersImmune Cell Function and Interaction

Cited by 14